Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
Annals of Internal Medicine2017Vol. 166(9), pp. 637–648
Citations Over TimeTop 1% of 2017 papers
Oluwaseun Falade‐Nwulia, Catalina Suarez‐Cuervo, David R. Nelson, Michael Fried, Jodi B Segal, Mark Sulkowski
Abstract
Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42014009711).
Related Papers
- → Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C(2016)21 cited
- → Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)(2020)5 cited
- → Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?(2014)4 cited
- → 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin(2016)
- → TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 PATIENT WITH TRIPLE THERAPY PEG-IFN, RIBAVIRIN AND SOFOSBUVIR: CASE REPORT AND REVIEW OF LITERATURE(2017)